Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML

Phase 2

Not yet recruiting

• Conditions: Acute Myeloid Leukemia
• Interventions: Drug: MCBC regimen; Drug: Bu/Cy regimen

• Registration Number: NCT06133556
• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Brief Summary

This project is a prospective, multicenter, randomized controlled clinical study. The subjects were refractory / relapsed AML patients aged ≤ 60 years diagnosed by bone marrow cell morphology, immunology, genetics and therapeutic efficacy evaluation. The classical Bu / Cy scheme or MCBC scheme was used for pretreatment. The primary endpoint of the study was the 3-year recurrence-free survival rate after allogeneic hematopoietic stem cell transplantation, and the secondary endpoints were 3-year overall survival rate, recurrence rate, treatment-related mortality, and pretreatment-related toxicity.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-09
• Study First Submitted: 2023-09-08
• Study First Submitted QC: 2023-11-13
• Last Update Submitted: 2023-11-13
• Study First Posted: 2023-11-15
• Last Update Posted: 2023-11-15
• Study Start: 2023-11-24
• Primary Completion: 2028-10-20
• Study Completion: 2028-10-20

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 237

Inclusion Criteria

• Refractory / relapsed AML.
• Patients with a HLA matched related or unrelated donor (9~10/10) or haplo-identical related donor, plan to receive HSCT.
• Age ≤ 60 years old, men and women are not limited.
• The Eastern Oncology Collaborative Group Physical Status Assessment ( ECOG-PS ) was 0-2 points.
• Informed consent must be signed before the start of the study procedure. Informed consent must be signed by the patient or his or her immediate family members who are 18 years of age or older ; informed consent was signed by the legal guardian for children and adolescent patients under 18 years old. Considering the patient 's condition, if the patient 's signature is not conducive to the treatment of the disease, the informed consent is signed by the legal guardian or the patient 's immediate family.

Exclusion Criteria

• Have a history of cancer and have received any treatment for this tumor in the past 3 years. But remove superficial bladder cancer, skin basal cells or squamous cell carcinoma, cervical epithelium. Intraepithelial neoplasia ( CIN ) or prostatic intraepithelial neoplasia ( PIN ).

• MPAL.

• It is known that the serological reaction of HIV or active hepatitis C virus is positive.

• The inability to cooperate with the requirements of research, treatment and monitoring due to mental illness or other conditions.

• Pregnant patients or patients who could not take appropriate contraceptive measures during treatment.

• Previously received hematopoietic stem cell transplantation.

• Active heart disease, defined as one or more of the following :

  1. ) Uncontrolled or symptomatic angina history.
  2. ) Myocardial infarction less than 6 months away from the study.
  3. ) Have a history of arrhythmia requiring drug treatment or severe clinical symptoms.
  4. ) Uncontrolled or symptomatic congestive heart failure ( > NYHA class 2 ).
  5. ) The ejection fraction is lower than the lower limit of the normal range.

• Researchers evaluated that is not suitable for the group.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MCBC group	MCBC regimen	using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
control arm	Bu/Cy regimen	Busulfan/Cyclophosphamide, "standard" conditioning regimen as a control group. including Bu3.2mg/kg -5\~-3d; Cy 80mg/kg，-2\~-1d。 or alternative Bu/Cy regimen, Bu3.2mg/kg -9\~-7d；Flu 30mg/m2 -6\~-4d；Ara-C 2g/m2 -6\~-4d；Cy 80mg/kg -3\~-2d。

Primary Outcome Measures

Name	Time	Method
Relapse Free Survival	3 year post-HSCT	The AML relapse free survival post-HSCT

Secondary Outcome Measures

Name	Time	Method
Non-relapse mortality	3 year post-HSCT	Non-relapse mortality post-HSCT
toxicity of conditioning regimen	24w post-HSCT	Adverse events as assessed by CTCAE to evaluate conditioning related toxicity
Overall Survival	3 year post-HSCT	The overall survival post-HSCT
Immune reconstitution post-HSCT	24w post-HSCT	Using lymphocyte subset panel to assess immune recovery post-HSCT
cumulative incidence relapse rate	3 year post-HSCT	cumulative incidence relapse rate post-HSCT